Parvovirus B19 in pregnancy: Prenatal diagnosis and management of fetal complications

Current Opinion in Obstetrics and Gynecology

Volumn 24, Issue 2, 2012, Pages 95-101

  Dijkmans, Anneke C ^a,b   De Jong, Eveline P ^b   Dijkmans, Ben A C ^c   Lopriore, Enrico ^d   Vossen, Ann ^a   Walthere, Frans J ^d   Oepkes, Dick ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d Division of Neonatology   (Netherlands)

Author keywords

Fetal anemia; Fetal infection; Fetus; Hydrops; Parvovirus B19; Pregnancy

Indexed keywords

CLINICAL FEATURE; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FETUS DEATH; FETUS DISEASE; FETUS HYDROPS; HUMAN; HUMAN PARVOVIRUS B19; NEUROLOGIC DISEASE; PARVOVIRUS INFECTION; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREGNANCY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EARLY DIAGNOSIS; ERYTHEMA INFECTIOSUM; FEMALE; FETAL DISEASES; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MIDDLE CEREBRAL ARTERY; PARVOVIRIDAE INFECTIONS; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL DIAGNOSIS; ULTRASONOGRAPHY, PRENATAL;

EID: 84859749108     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3283505a9d     Document Type: Review

References (47)

1. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975; 1:72-73.
2. Siegl G, Bates RC, Berns KI, et al. Characteristics and taxonomy of Parvoviridae. Intervirology 1985; 23:61-73. (Pubitemid 15165358)
3. Anderson LJ. Human parvoviruses. J Infect Dis 1990; 161:603-608. (Pubitemid 20120214)
4. Anderson MJ, Lewis E, Kidd IM, et al. An outbreak of erythema infectiosum associated with human parvovirus infection. J Hyg (Lond) 1984; 93:85-93. (Pubitemid 14030339)
5. Pattison JR, Jones SE, Hodgson J, et al. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet 1981; 1:664-665.
6. Cohen BJ, Mortimer PP, Pereira MS. Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV). J Hyg (Lond) 1983; 91:113-130. (Pubitemid 14229522)
7. Edwards JM, Kessel I, Gardner SD, et al. A search for a characteristic illness in children with serological evidence of viral or toxoplasma infection. J Infect 1981; 3:316-323.
8. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152:257-265. (Pubitemid 15001320)
9. Anderson MJ, Pattison JR. The human parvovirus. Brief review. Arch Virol 1984; 82:137-148.
10. Dijkmans BA, Breedveld FC, Weiland HT. Acute joint symptoms in a parvovirus infection. Ned Tijdschr Geneeskd 1986; 130:1702-1705. (Pubitemid 16017054)
11. Dijkmans BA, van Elsacker-Niele AM, Salimans MM, et al. Human parvovirus B19 DNA in synovial fluid. Arthritis Rheum 1988; 31:279-281. (Pubitemid 18088050)
12. Bell LM, Naides SJ, Stoffman P, et al. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med 1989; 321:485-491. (Pubitemid 19203871)
13. Enders M, Weidner A, Zoellner I, et al. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: Prospective evaluation of 1018 cases. Prenat Diagn 2004; 24:513-518. (Pubitemid 39061905)
14. Kooistra K, Mesman HJ, de Waal M, et al. Epidemiology of high-level parvovirus B19 viraemia among Dutch blood donors. Vox Sang 2011; 100:261-266.
15. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002; 15:485-505. (Pubitemid 34761354)
16. Rohrer C, Gartner B, Sauerbrei A, et al. Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect 2008; 136:1564-1575.
17. de Jong EP, de Haan TR, Kroes AC, et al. Parvovirus B19 infection in pregnancy. J Clin Virol 2006; 36:1-7. (Pubitemid 44360575)
18. Valeur-Jensen AK, Pedersen CB, Westergaard T, et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA 1999; 281:1099-1105. (Pubitemid 29155886)
19. Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. BMJ 1990; 300:1166-1170.
20. Chisaka H, Morita E, Yaegashi N, Sugamura K. Parvovirus B19 and the pathogenesis of anaemia. Rev Med Virol 2003; 13:347-359. (Pubitemid 37413257)
21. Norbeck O, Papadogiannakis N, Petersson K, et al. Revised clinical presentation of parvovirus B19-associated intrauterine fetal death. Clin Infect Dis 2002; 35:1032-1038. (Pubitemid 35239461)
22. Enders M, Klingel K, Weidner A, et al. Risk of fetal hydrops and nonhydropic late intrauterine fetal death after gestational parvovirus B19 infection. J Clin Virol 2010; 49:163-168. This relatively large observational study shows a 10.6% risk of fetal hydrops in women infected between 9 and 20 weeks' gestation.
23. Yaegashi N. Pathogenesis of nonimmune hydrops fetalis caused by intrauterine B19 infection. Tohoku J Exp Med 2000; 190:65-82.
24. Brkic S, Bogavac MA, Simin N, et al. Unusual high rate of asymptomatic maternal parvovirus B19 infection associated with severe fetal outcome. J Matern Fetal Neonatal Med 2011; 24:647-649.
25. van Kamp IL, Klumper FJ, Bakkum RS, et al. The severity of immune fetal hydrops is predictive of fetal outcome after intrauterine treatment. Am JObstet Gynecol 2001; 185:668-673. (Pubitemid 32862557)
26. Bonvicini F, Puccetti C, Salfi NC, et al. Gestational and fetal outcomes in b19 maternal infection: A problem of diagnosis. J Clin Microbiol 2011; 49:3514-3518. This cohort study showed that neither B19 IgM nor B19 DNA detected all maternal infections. IgM serology correctly diagnosed 94.1% of the B19 infections, while DNA testing correctly diagnosed 96.3%. Combining both methods provided the best sensitivity. B19 vertical transmission was observed in 39% of the pregnancies, with an overall 10.2% rate of fetal deaths.
27. Bonvicini F, Manaresi E, Gallinella G, et al. Diagnosis of fetal parvovirus B19 infection: Value of virological assays in fetal specimens. BJOG 2009; 116:813-817.
28. de Haan TR, Beersma MF, Claas EC, et al. Parvovirus B19 infection in pregnancy studied by maternal viral load and immune responses. Fetal Diagn Ther 2007; 22:55-62. (Pubitemid 44973709)
29. Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med 2006; 260:285-304. (Pubitemid 44370903)
30. Pasquinelli G, Bonvicini F, Foroni L, et al. Placental endothelial cells can be productively infected by Parvovirus B19. J Clin Virol 2009; 44:33-38.
31. Koch WC, Harger JH, Barnstein B, Adler SP. Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B19 with a primary maternal infection during pregnancy. Pediatr Infect Dis J 1998; 17:489-494. (Pubitemid 28287615)
32. Nyman M, Skjoldebrand-Sparre L, Broliden K. Nonhydropic intrauterine fetal death more than 5 months after primary parvovirus B19 infection. J Perinat Med 2005; 33:176-178. (Pubitemid 40477081)
33. Yaegashi N, Niinuma T, Chisaka H, et al. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. J Infect 1998; 37:28-35. (Pubitemid 28421200)
34. Simms RA, Liebling RE, Patel RR, et al. Management and outcome of pregnancies with parvovirus B19 infection over seven years in a tertiary fetal medicine unit. Fetal Diagn Ther 2009; 25:373-378.
35. Nunoue T, Kusuhara K, Hara T. Human fetal infection with parvovirus B19: Maternal infection time in gestation, viral persistence and fetal prognosis. Pediatr Infect Dis J 2002; 21:1133-1136. (Pubitemid 35463029)
36. de Haan TR, Van den Akker ESA, Porcelijn L, et al. Thrombocytopenia in hydropic fetuses with parvovirus B19 infection: Incidence, treatment and correlation with fetal B19 viral load. BJOG 2008; 115:76-81. (Pubitemid 350209614)
37. Pistorius LR, Smal J, de Haan TR, et al. Disturbance of cerebral neuronal migration following congenital parvovirus B19 infection. Fetal Diagn Ther 2008; 24:491-494.
38. Isumi H, Nunoue T, Nishida A, Takashima S. Fetal brain infection with human parvovirus B19. Pediatr Neurol 1999; 21:661-663. (Pubitemid 29461002)
39. Dembinski J, Haverkamp F, Maara H, et al. Neurodevelopmental outcome after intrauterine red cell transfusion for parvovirus B19-induced fetal hydrops. BJOG 2002; 109:1232-1234. (Pubitemid 36167827)
40. Nagel HT, de Haan TR, Vandenbussche FP, et al. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection. Obstet Gynecol 2007; 109:42-47. (Pubitemid 46035508)
41. Beersma MF, Claas EC, Sopaheluakan T, Kroes AC. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples. J Clin Virol 2005; 34:71-75. (Pubitemid 41125879)
42. Bredl S, Plentz A, Wenzel JJ, et al. False-negative serology in patients with acute parvovirus B19 infection. J Clin Virol 2011; 51:115-120. This analysis of samples from blood donors and patients with suspected parvovirus B19 infections clerly showed the unreliability of simple IgM/IgG evaluation. Antibodies against the capsid proteins VP1 and VP2 may complex with B19Vparticles thereby becoming undetectable in diagnostic tests.
43. Enders M, Helbig S, Hunjet A, et al. Comparative evaluation of two commercial enzyme immunoassays for serodiagnosis of human parvovirus B19 infection. J Virol Methods 2007; 146:409-413. (Pubitemid 350030950)
44. Enders M, Weidner A, Rosenthal T, et al. Improved diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops. J Infect Dis 2008; 197:58-62. (Pubitemid 351263466)
45. de Haan TR, Beersma MF, Oepkes D, et al. Parvovirus B19 infection in pregnancy: Maternal and fetal viral load measurements related to clinical parameters. Prenat Diagn 2007; 27:46-50. (Pubitemid 46144340)
46. Delle Chiaie L, Buck G, Grab D, Terinde R. Prediction of fetal anemia with Doppler measurement of the middle cerebral artery peak systolic velocity in pregnancies complicated by maternal blood group alloimmunization or parvovirus B19 infection. Ultrasound Obstet Gynecol 2001; 18:232-236. (Pubitemid 32830494)
47. Ballou WR, Reed JL, Noble W, et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003; 187:675-678. (Pubitemid 36250032)